Aloperine in combination with therapeutic adenoviral vector synergistically suppressed the growth of non-small cell lung cancer

ConclusionIn conclusion, ALO –Adbic combination can produce synergistic anti-cancer effects at low doses, and may offer a more effective and less toxic new treatment strategy for NSCLC.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Publication date: Available online 6 April 2020Source: Journal of the American Society of CytopathologyAuthor(s): Rachel Jug, Coral X. Giovacchini, Beiyu Liu, Cindy Green, Jeffrey M. Clarke, Kamran Mahmood, Elizabeth N. Pavlisko
Source: Journal of the American Society of Cytopathology - Category: Cytology Source Type: research
Cancers, Vol. 12, Pages 896: Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch® and ISET Cancers doi: 10.3390/cancers12040896 Authors: Tamminga Andree Hiltermann Jayat Schuuring van den Bos Spierings Lansdorp Timens Terstappen Groen Circulating tumor cells (CTCs) detected by CellSearch are prognostic in non-small-cell lung cancer (NSCLC), but rarely found. CTCs can be extracted from the blood together with mononuclear cell populations by diagnostic leukapheresis (DLA), therefore concentrating th...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
AbstractLymph node assessment is an essential component of the treatment of lung cancer. Identification of the correct “N” stage is important for staging which in turn determines treatment. Assessment of lymph nodes may be accomplished using imaging with CT scan and PET–CT, invasive techniques such as mediastinoscopy, endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) or endoscopic ultrasoun d fine needle aspiration (EUS-FNA). Ultimately, regardless of any pre-resection assessment, lymph nodes must be assessed at the time of resection. The question to be addressed in this report is the ...
Source: General Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Hypofractionated curative radiotherapy in doses up to 60 Gy at 4 Gy per fraction is tolerable in patients with unresectable stage III non-small-cell lung cancer, with encouraging preliminary survival.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
Contributors : Xiangzhen Kong ; Shousen HuSeries Type : Expression profiling by high throughput sequencing ; Non-coding RNA profiling by high throughput sequencingOrganism : Homo sapiensWe detected the expression profiles ofcircRNAs, lncRNAs and mRNAs in two drug-resistant NSCLC cell lines (A549/R and HCC827/R) and their parent cell lines (A549 and HCC827) by RNA sequencing, employed a com ­prehensive analysis of the dysregulated lncRNAs, miRNAs and mRNAs by bioinformatics methods.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Non-coding RNA profiling by high throughput sequencing Homo sapiens Source Type: research
CONCLUSION: Here, we present what, to the best of our knowledge, is the first reported case in which durvarumab resistance after definitive chemoradiotherapy in a patient with stage III pulmonary sarcomatoid carcinoma was overcome by pembrolizumab. PMID: 32245391 [PubMed - as supplied by publisher]
Source: BMC Pharmacology and Toxicology - Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research
While epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) exert a breakthrough effect, the incidence of skin disorders as a side effect has significantly reduced patients ’ quality of life...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
There is no consensus on the therapeutic approach to ECOG 2 patients with locally advanced non-small-cell lung cancer (LA-NSCLC), despite the sizable percentage of these patients in clinical practice. This stu...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
ConclusionsCurrent clinical trials are exploring combination therapy and novel treatment strategies beyond immune checkpoint therapies and vaccine therapy such as CAR T cells. There is also an effort to establish synergy between immunotherapy and current standard of care. Furthermore, recent advances in personalized neoantigen vaccines suggest a shift towards personalized, patient-specific GBM treatment.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Complementary Medicine | Gene Therapy | Genetics | Herbs | Lung Cancer | Non-Small Cell Lung Cancer | Study | Toxicology | Women